文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

水飞蓟素治疗非酒精性脂肪性肝病患者的疗效——Siliver试验:一项随机对照临床试验的研究方案

Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2023-03-10

本研究为随机双盲安慰剂对照临床试验,招募门诊成年非酒精性脂肪性肝病(NAFLD)患者,干预组每日接受水飞蓟素700mg+维生素E 8mg+磷脂酰胆碱50mg,对照组每日接受麦芽糊精700mg+维生素E 8mg+磷脂酰胆碱50mg,随访12周,主要结局为腹部CT肝脾衰减系数差值评估的NAFLD分期变化。

要点

  • 水飞蓟素组每日700mg水飞蓟素+8mg维生素E+50mg磷脂酰胆碱,对照组以700mg麦芽糊精替代水飞蓟素。
  • 主要结局为基线与12周时腹部CT肝脾衰减系数差值所评估的NAFLD分期变化。
  • 研究结果可能为水飞蓟素能否作为NAFLD辅助治疗提供依据。

核心结论

  • 本研究结果可能为水飞蓟素能否用于NAFLD的辅助管理或治疗提供有价值的意见。
  • 关于水飞蓟素疗效和安全性的数据可能为进一步试验及可能的临床实践应用提供更多基础。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,招募门诊接受治疗的成年NAFLD患者,随机分为干预组(I)和对照组(C),随访12周。

主要发现

  • 干预组每日接受水飞蓟素700mg+维生素E 8mg+磷脂酰胆碱50mg,对照组每日接受麦芽糊精700mg+维生素E 8mg+磷脂酰胆碱50mg。
  • 两组均在研究开始和结束时接受计算机断层扫描(CT)和血液检查,所有参与者每月面对面咨询、每周电话联系。
  • 主要结局为通过上腹部CT获得的肝脾衰减系数差值评估的NAFLD分期变化(如有)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases globally. Pharmacological treatments for NAFLD are still limited. Silymarin, a compound extracted from Silybum marianum, is an herbal supplement traditionally used in folk medicine for liver disorders. It has been proposed that silymarin may possess hepatoprotective and anti-inflammatory properties. The present trial aims to assess the efficacy of silymarin supplementation in the adjuvant treatment of NAFLD in adult patients. METHOD: This is a randomized double-blind placebo-controlled clinical trial recruiting adult NAFLD patients in therapy on an outpatient basis. Participants are randomized to an intervention (I) or control (C) group. Both groups receive identical capsules and are followed for 12 weeks. I receives 700mg of silymarin + 8mg vitamin E + 50mg phosphatidylcholine daily, while C receives 700mg maltodextrin + 8mg vitamin E + 50mg phosphatidylcholine daily. Patients undergo a computerized tomography (CT) scan and blood tests at the beginning and end of the study. Monthly face-to-face consultations and weekly telephone contact are carried out for all participants. The primary outcome assessed will be change in NAFLD stage, if any, assessed by the difference in attenuation coefficient between liver and spleen, obtained by upper abdomen CT. DISCUSSION: The results of this study may provide a valuable opinion on whether silymarin can be used as adjuvant therapy for the management or treatment of NAFLD. The data presented on the efficacy and safety of silymarin may provide more foundation for further trials and for a possible use in clinical practice. TRIAL REGISTRATION: This study has been approved by the Research Ethics Committee of the Professor Edgard Santos University Hospital Complex, Salvador BA, Brazil, under protocol 2.635.954. The study is carried out according to guidelines and regulatory standards for research involving humans, as set out in Brazilian legislation. Trial registration - ClinicalTrials.gov : NCT03749070. November 21, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. de Avelar CR, Nunes BVC, da Silva Sassaki B, et al. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial. Trials. 2023. PMID: 36899430. doi:10.1186/s13063-023-07210-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。